<DOC>
	<DOCNO>NCT01399450</DOCNO>
	<brief_summary>The purpose study change ( improve ) , initiate various dos Paliperidone ER schizophrenia patient .</brief_summary>
	<brief_title>Paliperidone ER ( Invega® ) Depressive Symptoms Schizophrenia Patients</brief_title>
	<detailed_description>In study , investigator go examine effectiveness Paliperidone ER depressive symptom toward schizophrenia patient previously unresponsive oral antipsychotic . In addition , relationship change depressive symptom adherence study . Even though study limitation design open-labelled clinical study , would useful clinician study examines influence toward adherence relate various factor change depressive symptom related switch Paliperidone ER , well-proven medication .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Age : 18 ~ 65 Patient schizophrenia accord DSMIV criterion Patient sign informed consent , well understood objective procedure study . Patient need initiation new antipsychotic due newlydevelopment recurrence acute psychosis MADRS≥16 Competent patient manage answer questionnaire . In case female childbearing age , consent use appropriate contraceptive method ( oral pill , contraceptive injection , intrauterine device , double barrier method contraceptive patch ) entire duration study . Past history NMS . Allergy hypersensitivity Risperidone Paliperidone ER . History use clozapine within 1 month screening . Initiating dosechanging SSRI , MAOI , TCA within 2 month ( maintenance allow stable least 30days prior study entry would dose change study ) . Initiating Lithium , Valproic acid , Carbamazepine , Topiramate , Lamotrigine mood stabilizer within 2months ( maintenance allow ) . Patient suppose impossible participate study due clinical risk suicide aggressive behavior base clinician 's opinion . History severe gastrointestinal obstruction ( pathologic iatrogenic ) incapacity swallow drug form ( allow chew , divide , dissolve make powder clinical trial medication due possibility influence pharmacokinetics ) Current substance dependence ( DSMIV ) past history dependence ( 6months ) Significant biochemical hematological abnormality abnormal finding urinalysis , base clinician 's opinion . History cardiac disease predispose QT prolongation ( sick sinus , complete AV block , CHF , ventricular tachycardia , hypokalemia hypocalcemia ) current medication QT prolong drug Patients take QT prolong drug Pregnant breastfeed female patient . History participate investigational drug trial within 1month prior screening . History take longacting antipsychotic injection within 3month screening . Investigator employee clinical trial center , personnel relate investigator trial center study , family employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Schizophrenia , depressive symptom , paliperidone</keyword>
</DOC>